Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nanjing Boan Biotechnology Co. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit. The busiest examiner for the company is DENT, ALANA HARRIS, who is managing 1 pending office action. Prosecution for this company is currently centralized, with all active feedback originating from a single examiner within the Biotechnology & Pharmaceuticals field.
Practitioners should focus exclusively on the preferences of DENT, ALANA HARRIS to advance this case. The lack of multiple pending actions or examiners means there is no internal baseline for comparing prosecution success or examiner behavior. This company's strategy is currently tied to the resolution of this 1 pending office action. The outcome of this single case will define the current success of the patenting effort, making the interaction with the 1 distinct examiner the central element of the prosecution process. This singular focus within 1 art unit simplifies the administrative tracking but increases the impact of any single examiner's decision on the overall portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DENT, ALANA HARRIS | 1 | 44.1% | +32.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682673 | ROR1 CAR or ROR1 / CD19 Dual CAR T Cells for the Treatment of Tumors | DENT, ALANA HARRIS | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682673 | ROR1 CAR or ROR1 / CD19 Dual CAR T Cells for the Treatment of Tumors | DENT, ALANA HARRIS | 1643 | §112 | Non-Final OA | — | Pending | Feb 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNanjing Boan Biotechnology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alana Harris Dent has the most, with 1 of Nanjing Boan Biotechnology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
